reBEAT: Biventricular Epicardial Augmentation Technology for HF Patients: Introducing a Novel MCS Technology, First-in-Human Translational Insights, Strategy for Pivotal Trial and Market Entry

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Equity/Stock(s)/Options - AdjuCor GmbH